LARK.ST Novakand Pharma AB (publ)
- Market cap
- SEK 44.8M
- P/E
- 37.7x
- P/B
- 0.79x
- ROE
- 4.3%
- Dividend yield
- 8.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LARK.ST undervalued?
Graham numberLARK.ST trades 15.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novakand Pharma AB (publ) fundamental analysis
No fundamental analysis for Novakand Pharma AB (publ) yet.
Novakand Pharma AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novakand Pharma AB (publ)
Lärkberget AB (publ) operates as an investment company. The company is involved in direct investments in low-risk instruments, and unlisted profitable companies; financial investments; and reverse acquisition business. It also invests in listed shares, funds and other liquid asset classes, as well as participates in bridge loans and guarantee commitments. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberg…
Full company profileNovakand Pharma AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novakand Pharma AB (publ) annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 3.00M | 8.15K | 15.0M | 10.8M | 84.0M | 26.7M | 5.54M | 326K | 0.00 | 200K |
| Gross Profit | -7.25M | -9.41M | -11.4M | 13.8M | 8.33M | 15.2M | -19.2M | -21.3M | -46.8M | -8.16M | -2.15M |
| Operating Income | -8.67M | -8.96M | -13.2M | -17.7M | -28.2M | 21.0M | -6.95M | -38.6M | -47.2M | -13.0M | -4.04M |
| EBITDA | 406.00 | 22.00 | 465K | -16.5M | -25.7M | 23.6M | -5.86M | -36.0M | -43.1M | -7.19M | - |
| Net Income | -8.67M | -8.96M | -13.1M | -17.8M | -30.8M | 21.0M | -6.16M | -35.7M | -44.9M | -12.4M | 2.44M |
| EPS | -8.08 | -11 | -9.47 | -6.01 | -3.34 | 1.21 | -0.31 | -1.80 | -2.27 | -0.62 | 0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 4.89M | 8.14M | 35.1M | 43.8M | 79.4M | 166M | 158M | 121M | 75.9M | 56.7M | 57.6M |
| Total Liabilities | 810K | 1.63M | 14.7M | 23.5M | 7.98M | 7.94M | 6.10M | 4.16M | 4.30M | 1.24M | 846K |
| Shareholders' Equity | 4.08M | 6.51M | 20.5M | 18.5M | 71.4M | 158M | 152M | 116M | 71.6M | 55.5M | 56.7M |
| Cash & Short-term Investments | 3.05M | 4.92M | 31.8M | 13.2M | 48.9M | 137M | 132M | 101M | 73.7M | 5.84M | 6.17M |
| Total Debt | - | - | - | 7.00M | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.81M | -9.53M | 228K | -21.6M | -38.3M | 22.1M | -16.7M | -30.6M | -29.9M | -12.8M | 1.41M |
| Capital Expenditure | 77.3K | 0.00 | 430K | 0.00 | 104K | 148K | 0.00 | 109K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -8.89M | -9.53M | -203K | -21.6M | -38.4M | 22.0M | -16.7M | -30.7M | -29.9M | -12.8M | 1.41M |
| Ratios | |||||||||||
| ROE | -212.4% | -137.6% | -64.3% | -96.6% | -43.1% | 13.2% | -4.0% | -30.6% | -62.7% | -22.3% | 4.3% |
| ROA | -177.2% | -110.1% | -37.4% | -40.7% | -38.8% | 12.6% | -3.9% | -29.6% | -59.1% | -21.8% | 4.2% |
| Net Profit Margin | - | -298.6% | -161,379.8% | -119.0% | -284.2% | 24.9% | -23.1% | -643.3% | -13,766.3% | - | 1,221.0% |
| Debt to Equity | - | - | - | 0.38x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novakand Pharma AB (publ) dividends
- Dividend yield
- 8.85%
- Forward dividend
- 2.00 SEK
- Payout ratio
- -
- Ex-dividend date
- May 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 3.96M | 0.20 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Jun 7, 2021.
Who owns Novakand Pharma AB (publ)
- Insiders 46.10%
- Institutions 12.11%
- Public & others 41.79%
- Shares outstanding 19.8M
- Free float 11.7M
Novakand Pharma AB (publ) company profile
- Company name
- Novakand Pharma AB (publ)
- Ticker
- LARK.ST
- ISIN
- SE0016101935
- Exchange
- Stockholm Exchange
- Sector
- Financial Services
- Industry
- Asset Management
- Employees
- 1
- Fiscal year end
- December
- Address
- Aboutvalue, Östermalm, Sweden, 114 34
- Phone
- 46 7 35 30 37 98
- Website
- larkberget.se
About Novakand Pharma AB (publ)
Lärkberget AB (publ) operates as an investment company. The company is involved in direct investments in low-risk instruments, and unlisted profitable companies; financial investments; and reverse acquisition business. It also invests in listed shares, funds and other liquid asset classes, as well as participates in bridge loans and guarantee commitments. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberget AB (publ) was incorporated in 1990 and is based in Östermalm, Sweden.
Novakand Pharma AB (publ) management
2- Mr. Luca Emiliano Di StefanoChief Executive Officer · born 1978
- Ms. Annika EricssonChief Scientific Officer